SCHEMBL6005672

SCHEMBL6005672

CN(C)[C@@H](Cc1ccc(Cl)cc1Cl)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 6/20 0.45
EPHX1 P07099 2/20 0.43
CYP3A4 P08684 3/20 0.42
CYP2C9 P11712 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
ERCC1 P07992 1/20 0.42
ERCC4 Q92889 1/20 0.42
GAA P10253 1/20 0.42
FSCN1 Q16658 1/20 0.41
NR4A2 P43354 1/20 0.41
PYCR1 P32322 1/20 0.41
KMT2A Q03164 1/20 0.41
UGCG Q16739 1/20 0.41
IDO1 P14902 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28396514 0.81 CYP3A4 (0.49) HDAC8CYP3A4CYP2C9ERCC1ERCC4
SCHEMBL14435582 0.80 IDO1 (0.42) HDAC8CYP3A4CYP2C9GAANR4A2
SCHEMBL11458388 0.80 IDO1 (0.49) HDAC8EPHX1CYP3A4CYP2C9HDAC3
SCHEMBL9780834 0.79 CYP3A4 (0.52) HDAC8EPHX1CYP3A4CYP2C9HDAC3
SCHEMBL6005671 0.79 CYP3A4 (0.52) HDAC8EPHX1CYP3A4CYP2C9HDAC3
SCHEMBL8591917 0.78 IDO1 (0.47) HDAC8EPHX1CYP3A4CYP2C9HDAC3
SCHEMBL13941148 0.78 IDO1 (0.47) HDAC8EPHX1CYP3A4CYP2C9HDAC3
SCHEMBL28322156 0.78 HDAC8 (0.47) HDAC8EPHX1CYP3A4CYP2C9HDAC3
SCHEMBL12210555 0.76 HDAC8 (0.40) HDAC8CYP3A4HDAC3HDAC1HDAC2
SCHEMBL44905 0.76 HDAC8 (0.58) HDAC8CYP3A4CYP2C9HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP HDAC8 2140/4885EPHX1 818/4885CYP3A4 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.